Literature DB >> 2591643

Circulating insulin-like growth factor I in type 1 (insulin-dependent) diabetic patients with retinopathy.

P Arner1, S Sjöberg, M Gjötterberg, A Skottner.   

Abstract

The relationship between insulin-like growth factor I (IGF I) and diabetic retinopathy was investigated. This somatomedin circulates bound to at least two large carrier proteins with molecular weights of approximately 150,000 and 35,000. Total and protein binding profiles of insulin-like growth factor I were determined in the serum of 18 patients who had had Type 1 (insulin-dependent) diabetes for 15-20 years, but had no signs of nephropathy and a similar degree of mild subclinical neuropathy. Nine had preproliferative or proliferative retinopathy and 9 had little or no background retinopathy but there was no difference in diabetes duration, insulin doses or glycaemic control between the two groups. In the latter group, the amounts of the somatomedin I and the serum profiles were similar to those in 9 healthy control subjects. In patients with advanced retinopathy, however, binding of insulin-like growth factor I to the carrier proteins was significantly altered. Binding to the low molecular weight protein increased to 140% whereas binding to the large molecular weight protein decreased to 70% of the normal level. In the latter Type 1 diabetic patients total serum insulin-like growth factor I was decreased to 60% of the normal level (p less than 0.02). When the alteration in serum profile was adjusted for, the level of somatomedin associated with the small carrier complex was normal whereas that associated with the large carrier complex was reduced by almost 60% in Type 1 diabetic patients with retinopathy. It is proposed that the total circulating somatomedin level is low in advanced diabetic retinopathy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591643     DOI: 10.1007/bf00274537

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

2.  Immunoreactive somatomedin A in human serum.

Authors:  K Hall; J Brandt; G Enberg; L Fryklund
Journal:  J Clin Endocrinol Metab       Date:  1979-02       Impact factor: 5.958

3.  Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein.

Authors:  A M Suikkari; V A Koivisto; E M Rutanen; H Yki-Järvinen; S L Karonen; M Seppälä
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958

4.  Somatomedin on insulin-dependent diabetes mellitus.

Authors:  M P Cohen; K Jasti; D L Rye
Journal:  J Clin Endocrinol Metab       Date:  1977-08       Impact factor: 5.958

5.  An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I.

Authors:  R G Elgin; W H Busby; D R Clemmons
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.

Authors:  W H Daughaday; I K Mariz; S L Blethen
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

7.  Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age.

Authors:  K Tan; R C Baxter
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

8.  Von Willebrand factor (VIII R:Ag), fibronectin, and insulin-like growth factors I and II in diabetic retinopathy and nephropathy.

Authors:  R P Lamberton; A D Goodman; A Kassoff; C L Rubin; D H Treble; T M Saba; T J Merimee; W J Dodds
Journal:  Diabetes       Date:  1984-02       Impact factor: 9.461

9.  Insulin-like growth factors. Studies in diabetics with and without retinopathy.

Authors:  T J Merimee; J Zapf; E R Froesch
Journal:  N Engl J Med       Date:  1983-09-01       Impact factor: 91.245

10.  Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma.

Authors:  R C Baxter; J L Martin
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

View more
  6 in total

1.  Proliferative retinopathy with growth hormone deficiency and diabetes mellitus.

Authors:  J D Quin; A C MacCuish; D Gordon
Journal:  BMJ       Date:  1990-06-16

2.  Microvascular complications and the diabetic pregnancy.

Authors:  Melton J Bond; Jason G Umans
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

3.  Colocalisation of insulin and IGF-1 receptors in cultured rat sensory and sympathetic ganglion cells.

Authors:  S N Karagiannis; R H King; P K Thomas
Journal:  J Anat       Date:  1997-10       Impact factor: 2.610

4.  Serum levels of growth hormone-binding protein and insulin-like growth factor I in children and adolescents with type 1 (insulin-dependent) diabetes mellitus.

Authors:  G Massa; L Dooms; R Bouillon; M Vanderschueren-Lodeweyckx
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

Review 5.  Circulating biomarkers in glaucoma, age-related macular degeneration, and diabetic retinopathy.

Authors:  Madhu Nath; Nabanita Halder; Thirumurthy Velpandian
Journal:  Indian J Ophthalmol       Date:  2017-03       Impact factor: 1.848

6.  Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats.

Authors:  Predrag Serbedžija; Douglas N Ishii
Journal:  Indian J Endocrinol Metab       Date:  2012-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.